Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.58 and traded as high as $0.61. Protagenic Therapeutics shares last traded at $0.57, with a volume of 22,910 shares changing hands.
Protagenic Therapeutics Stock Down 3.4 %
The business's fifty day moving average is $0.48 and its two-hundred day moving average is $0.58. The company has a market cap of $9.81 million, a P/E ratio of -2.59 and a beta of 0.06. The company has a debt-to-equity ratio of 0.04, a quick ratio of 14.93 and a current ratio of 14.93.
Get
Protagenic Therapeutics alerts:
Protagenic Therapeutics (OTCMKTS:PTIX – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The biotechnology company reported ($0.05) earnings per share for the quarter.
Institutional Investors Weigh In On Protagenic Therapeutics
A hedge fund recently raised its stake in Protagenic Therapeutics stock. Renaissance Technologies LLC grew its holdings in Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 102,200 shares of the biotechnology company's stock after purchasing an additional 41,800 shares during the quarter. Renaissance Technologies LLC owned approximately 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 3.47% of the company's stock.
About Protagenic Therapeutics
(Get Rating)
Protagenic Therapeutics, Inc operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations.
Read More
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.58 and traded as high as $0.61. Protagenic Therapeutics shares last traded at $0.57, with a volume of 22,910 shares changing hands.
主角治療公司（OTCMKTS：PTIX-獲取評級）週一交易期間交易過程中超過其 200 天移動平均線的股票。該股票的兩百日移動平均線為 0.58 美元，交易高達 0.61 美元。主角治療股票最後交易價為 0.57 美元，成交量為 22,910 股。
Protagenic Therapeutics Stock Down 3.4 %
The business's fifty day moving average is $0.48 and its two-hundred day moving average is $0.58. The company has a market cap of $9.81 million, a P/E ratio of -2.59 and a beta of 0.06. The company has a debt-to-equity ratio of 0.04, a quick ratio of 14.93 and a current ratio of 14.93.
該企業的五十天移動平均線為 0.48 美元，其 200 日移動平均線為 0.58 美元。該公司的市值為 981 萬美元，市盈率為 -2.59，測試版為 0.06。該公司的債務與權益比率為 0.04，快速比率為 14.93，流動比率為 14.93。
Get
Protagenic Therapeutics
alerts:
Protagenic Therapeutics (OTCMKTS:PTIX – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The biotechnology company reported ($0.05) earnings per share for the quarter.
主角治療 (OTCMKTS: PTIX — 獲取評分) 上次公佈其季度收益數據週一, 11 月 14 日.該生物技術公司報告了本季度每股盈利（0.05 美元）。
Institutional Investors Weigh In On Protagenic Therapeutics
A hedge fund recently raised its stake in Protagenic Therapeutics stock. Renaissance Technologies LLC grew its holdings in Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 102,200 shares of the biotechnology company's stock after purchasing an additional 41,800 shares during the quarter. Renaissance Technologies LLC owned approximately 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 3.47% of the company's stock.
一家對沖基金最近增加了其在主角治療股票的股份。文藝復興技術有限責任公司增長了在主角治療, 公司. (OTCMKTS: PTIX-獲得評級) 69.2% 在第一季度, 根據該公司在其最近的 13F 申請與 SEC.該機構投資者在本季度額外購買 41,800 股股票後，擁有該生物技術公司股票的 102,200 股。在最近的報告期結束時，文藝復興技術有限責任公司擁有約 0.59% 的主角治療價值 83,000 美元。機構投資者和對沖基金擁有公司股票的 3.47％。
About Protagenic Therapeutics
Protagenic Therapeutics, Inc operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations.
主角治療, 公司經營作為一家生物技術公司.它從事治療藥物的發現和發展，以治療壓力相關的疾病，包括創傷後應激障礙，抑鬱症，焦慮和藥物和酒精成癮。該公司提供基於 PT00114 肽的配方。
Read More
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
- 獲取有關主角治療研究報告的免費副本
- 為什麼黃金現在可以成為您的投資組合中閃閃發光的補充
- SoFi 技術打破收益，但要小心美聯儲決定
- 購買高露潔棕櫚樹的浸
- 馬倫汽車在招聘狂歡, 這可能意味著什麼?
- 數位互聯提出其收益指引
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收主角治療的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關主角治療和相關公司的最新新聞和分析師評級的簡要每日摘要。
